LIREXAPRIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H36ClN3O2
Molecular Weight	434.015
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1CCN(C[C@H]2CCCC[C@H]2NC(=O)C3=CC(Cl)=C(N)C=C3OCC4CC4)CC1

InChI

InChIKey=PPVTTWPBNHFCAJ-XMSQKQJNSA-N

InChI=1S/C24H36ClN3O2/c1-16-8-10-28(11-9-16)14-18-4-2-3-5-22(18)27-24(29)19-12-20(25)21(26)13-23(19)30-15-17-6-7-17/h12-13,16-18,22H,2-11,14-15,26H2,1H3,(H,27,29)/t18-,22-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://adisinsight.springer.com/drugs/800005824 | https://www.ncbi.nlm.nih.gov/pubmed/22356640 | https://www.ncbi.nlm.nih.gov/pubmed/21413902

Lirexapride serotonin 5-HT4 receptor and dopamine D2 receptor agonists. It had been in phase II clinical trials for the treatment of irritable bowel syndrome. However, this research has been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Emerging drugs for functional dyspepsia.	2011 Jun	21413902
Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.	2012 Apr	22356640

Name

Type

Language

LIREXAPRIDE

Official Name

English

4-AMINO-5-CHLORO-.ALPHA.-CYCLOPROPYL-N-((1R,2R)-2-((4-METHYLPIPERIDINO)METHYL)CYCLOHEXYL)-O-ANISAMIDE

Common Name

English

lirexapride [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47794